Omega Therapeutics Inc at Chardan Genetic Medicines Conference Transcript
It's my pleasure to introduce our next guest from Omega Therapeutics: CEO Mahesh Karande, and CSO, Dr. Tom McCauley. Gentlemen, thank you for being with us today. Mahesh, maybe to start, can you provide an overview for the company and maybe talk about some of your key accomplishments in 2023 year to date?
Questions & Answers
Absolutely Keay. First of all, thanks a lot for having us at this conference and at this fireside chat, and thanks to you and Chardan. We are really excited to talk about Omega because Omega, as you know, as a company -- we just came out with clinical data in our first program for OTX-2002 in hepatocellular carcinoma.
And the reason these data are extremely significant is -- first of all, I mean, we'll talk more about the data, I'm sure -- but first of all, at this early stage, we are seeing a mechanism of action. So clinical proof of mechanism of action and mechanism of our platform in eight on eight patients. That is the the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |